DIO Corporation (KOSDAQ:039840)
9,680.00
-310.00 (-3.10%)
Sep 22, 2026, 3:30 PM KST
DIO Corporation Revenue
DIO Corporation had revenue of 44.95B KRW in the quarter ending June 30, 2026, with 12.10% growth. This brings the company's revenue in the last twelve months to 174.45B, up 20.26% year-over-year. In the year 2025, DIO Corporation had annual revenue of 164.08B with 37.13% growth.
Revenue (ttm)
174.45B
Revenue Growth
+20.26%
P/S Ratio
0.71
Revenue / Employee
377.59M
Employees
462
Market Cap
123.97B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 164.08B | 44.43B | 37.13% |
| Dec 31, 2024 | 119.65B | -36.17B | -23.21% |
| Dec 31, 2023 | 155.82B | 24.51B | 18.67% |
| Dec 31, 2022 | 131.31B | -18.73B | -12.48% |
| Dec 31, 2021 | 150.04B | 29.98B | 24.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.12T |
| Celltrion | 4.90T |
| Samsung Epis Holdings | 1.51T |
| Kyongbo Pharmaceutical | 279.55B |
| ALTEOGEN | 254.01B |
| Macrogen | 201.62B |
| Dongbang Medical | 125.12B |
| Shinhung | 105.89B |